Theralase Technologies Inc. (TSXV:TLT)
Canada · Delayed Price · Currency is CAD | Market Cap | 63.44M +44.5% |
| Revenue (ttm) | 816.47K -21.0% |
| Net Income | -4.12M |
| EPS | -0.02 |
| Shares Out | 275.82M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 50,659 |
| Average Volume | 683,942 |
| Open | 0.2400 |
| Previous Close | 0.2300 |
| Day's Range | 0.2300 - 0.2400 |
| 52-Week Range | 0.1450 - 0.4100 |
| Beta | 0.67 |
| RSI | 41.43 |
| Earnings Date | May 28, 2026 |
About Theralase Technologies
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of light activated photo dynamic compounds and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. The company operates through Drug Division and Device Division segments. It designs, develops, manufactures, and markets super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle... [Read more]
Financial Performance
In 2025, Theralase Technologies's revenue was 816,468, a decrease of -20.99% compared to the previous year's 1.03 million. Losses were -4.12 million, -3.18% less than in 2024.
Financial StatementsNews
Theralase(R) Closes C$4.8 Million Offering
Toronto, Ontario--(Newsfile Corp. - May 20, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the re...
Theralase Technologies Earnings Call Transcript: Q4 2025
Completed phase II bladder cancer study enrollment, reported strong interim efficacy and safety, and maintained disciplined financial management amid declining device revenues. Preparing for regulatory submissions in 2026 and expanding pipeline into multiple oncology and virology indications.
Theralase Technologies Registration statement: Q4 2025
Theralase Technologies filed a registration statement on May 12, 2026, providing details about a securities offering with the SEC.
Theralase Technologies Registration statement: Q4 2025
Theralase Technologies filed a registration statement on May 12, 2026, providing details about a securities offering with the SEC.
Theralase Technologies Earnings release: Q4 2025
Theralase Technologies released its Q4 2025 earnings on May 12, 2026, summarizing the period's financial results.
Theralase(R) Announces $4 Million Brokered LIFE Offering
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Toronto, Ontario--(Newsfile Corp. - May 5, 2026) - Theralase® Technologies Inc. (TSXV: TLT...
Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update
Toronto, Ontario--(Newsfile Corp. - May 4, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the res...
Theralase(R) Reports Complete Response with X-Ray-Activated Rutherrin(R) in Muscle Invasive Bladder Cancer Preclinical Study
Toronto, Ontario--(Newsfile Corp. - April 13, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the ...
Theralase(R) Closes $CAN 2.66 Million Financing
Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the ...
Theralase(R) Closes $1.1 M Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - March 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the ...
Theralase(R) Demonstrates That X-Ray-Activated Rutherrin(R) Is Significantly More Effective than Radiation Alone in the Destruction of Muscle Invasive Bladder Cancer
Toronto, Ontario--(Newsfile Corp. - March 9, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the r...
Correcting and Replacing: Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress
This Press Release identifies that Dr. Kulkarni has participated in a medical advisory position for Theralase(R) in the past. Toronto, Ontario--(Newsfile Corp. - February 20, 2026) - Theralase® Techno...
Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress
Toronto, Ontario--(Newsfile Corp. - February 17, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to t...
Theralase(R) Bladder Cancer Clinical Data to be Presented at the 2026 American Urological Association Annual Meeting
Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to t...
Theralase(R) Provides Update on Bladder Cancer Clinical Study
Interim clinical data has exceeded the recommended guidelines of the International Bladder Cancer Group for complete response and duration of complete response Toronto, Ontario--(Newsfile Corp. - Febr...
Ferring Pharmaceuticals and Theralase(R) Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer
The collaborative clinical study will evaluate ADSTILADRIN® (nadofaragene firadenovec-vncg) in combination with the investigational drug Ruvidar ® (TLD-1433) in patients with Bacillus Calmette-Guérin-...
Ferring Pharmaceuticals and Theralase® Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer
PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals and Theralase® Technologies Inc. (TSXV:TLT) (OTCQB:TLTFF) are pleased to announce that they have entered into a collaborative clinical develo...
Theralase(R) Closes $1.3 M Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - December 23, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering lig...
Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing
Toronto, Ontario--(Newsfile Corp. - December 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering lig...
Theralase(R) Announces Brokered LIFE Financing to Further Advance its Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
Toronto, Ontario--(Newsfile Corp. - November 24, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering lig...
Theralase(R) Investor Conference Call Reminder
Theralase(R) Reminds Investors of Conference Call to Provide Update on Study II Interim Data Demonstrating 64.3% Complete Response Toronto, Ontario--(Newsfile Corp. - November 17, 2025) - Theralase® T...
Theralase(R) Releases 3Q2025 Financial Statements
Toronto, Ontario--(Newsfile Corp. - November 10, 2025) - Theralase® Technologies Inc. (TSXV:TLT) (OTCQB:TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical pioneering light, radiat...
Theralase Technologies Registration statement: Q3 2025
Theralase Technologies filed a registration statement on November 10, 2025, providing details about a securities offering with the SEC.
Theralase Technologies Registration statement: Q3 2025
Theralase Technologies filed a registration statement on November 10, 2025, providing details about a securities offering with the SEC.
Theralase Technologies Earnings release: Q3 2025
Theralase Technologies released its Q3 2025 earnings on November 10, 2025, summarizing the period's financial results.